TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    F32CA009329     (HORTON, TERZAH M)Jan 25, 1993
    Role: Principal Investigator

    K23CA113775     (HORTON, TERZAH M)Jun 1, 2006 - May 31, 2011
    Proteosome Inhibition Therapy for Hematologic Malignancy
    Role: Principal Investigator

    R01CA164024     (HORTON, TERZAH M)Feb 5, 2013 - Jan 31, 2019
    Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
    Role: Principal Investigator

    R01CA193776     (TEACHEY, DAVID T)May 4, 2015 - Apr 30, 2021
    Improving risk allocation and developing novel therapies for children with T-ALL
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schraw JM, Woodhouse JP, Bernhardt MB, Taylor OA, Horton TM, Scheurer ME, Okcu MF, Rabin KR, Lupo PJ, Brown AL. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 Oct 04; 11(1):19613. PMID: 34608220.
      Citations:    Fields:    
    2. Abdelhamed S, Butler JT, Jung S, Chen DW, Jenkins GN, Gao L, Lim J, Klco JM, Horton TM, Kurre P. Rational biomarker development for the early and minimally invasive monitoring of AML. Blood Adv. 2021 Sep 29. PMID: 34587228.
      Citations:    Fields:    
    3. Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell MC, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Vrabic Koren J, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Defining the Transcriptional Control of Pediatric AML Highlights RARA as a Super-Enhancer Regulated Druggable Dependency. Blood Adv. 2021 Sep 20. PMID: 34543389.
      Citations:    Fields:    
    4. Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma. Int J Mol Sci. 2021 Jun 18; 22(12). PMID: 34207315.
      Citations:    Fields:    Translation:HumansAnimalsCells
    5. Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060. PMID: 32959058.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    6. Agrusa JE, Scull BP, Abhyankar HA, Lin H, Ozuah NW, Chakraborty R, Eckstein OS, Gulati N, Fattah EA, El-Mallawany NK, Rouce RH, Dreyer ZE, Brackett J, Margolin JF, Lubega J, Horton TM, Bollard CM, Gramatges MM, Kamdar KY, McClain KL, Man TK, Allen CE. Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers (Basel). 2020 Dec 02; 12(12). PMID: 33276546.
      Citations: 1     
    7. Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, Qiu Y, Wang T, Mo Q, Kornblau SM. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2021 02 20; 233:104046. PMID: 33212251.
      Citations:    Fields:    Translation:Humans
    8. Lyu A, Triplett TA, Nam SH, Hu Z, Arasappan D, Godfrey WH, Ames RY, Sarang A, Selden HJ, Lee CH, Georgiou G, Horton TM, Ehrlich LIR. Tumor-associated myeloid cells provide critical support for T-ALL. Blood. 2020 10 15; 136(16):1837-1850. PMID: 32845007.
      Citations: 1     Fields:    Translation:HumansCells
    9. Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020 Jun 23; 11(25):2387-2403. PMID: 32637030.
      Citations: 2     Fields:    
    10. Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, Jitkova Y, Nachmias B, MacLean N, Wang X, Arruda A, Minden MD, Horton TM, Kornblau SM, Chan SM, Bader GD, Raught B, Schimmer AD. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020 04 08; 12(538). PMID: 32269163.
      Citations: 11     Fields:    Translation:HumansCells
    11. Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, Kolb EA, Gamis A. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020 07; 105(7):1879-1886. PMID: 32029509.
      Citations: 17     Fields:    Translation:Humans
    12. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876. PMID: 31687977.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    13. Stevens AM, Xiang M, Heppler LN, Tošic I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227. PMID: 31856268.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    14. Abdelhamed S, Butler JT, Doron B, Halse A, Nemecek E, Wilmarth PA, Marks DL, Chang BH, Horton T, Kurre P. Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche. EMBO Rep. 2019 07; 20(7):e47546. PMID: 31267709.
      Citations: 8     Translation:HumansAnimalsCells
    15. Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. Br J Haematol. 2019 07; 186(2):274-285. PMID: 30957229.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    16. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238. PMID: 30122620.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    17. Hoff FW, Hu CW, Qutub AA, de Bont ESJM, Horton TM, Kornblau SM. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Expert Rev Proteomics. 2018 07; 15(7):613-622. PMID: 29898608.
      Citations:    Fields:    Translation:HumansAnimalsCells
    18. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Scheurer ME, de Bont ESJM, Qutub AA, Kornblau SM, Horton TM. Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Mol Cancer Res. 2018 08; 16(8):1263-1274. PMID: 29669823.
      Citations: 1     Fields:    Translation:Humans
    19. Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM, Kornblau SM. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets. Mol Cancer Res. 2018 08; 16(8):1275-1286. PMID: 29669821.
      Citations: 2     Fields:    Translation:Humans
    20. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999. PMID: 29305553.
      Citations: 32     Fields:    Translation:HumansAnimals
    21. Bhojwani D, Burke MJ, Horton T, Ziegler DS, Sulis ML, Schultz KR, Wayne A, Izraeli S, Chang BH. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. Pediatr Hematol Oncol. 2017 Sep - Oct; 34(6-7):355-364. PMID: 29190164.
      Citations:    Fields:    Translation:Humans
    22. Esbenshade AJ, Pierson CR, Thompson AL, Reed D, Gupta A, Levy A, Kahalley LS, Harker-Murray P, Schore R, Muscal JA, Embry L, Maloney K, Horton T, Zweidler-Mckay P, Dhall G. Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3). PMID: 29193588.
      Citations: 1     Fields:    Translation:Humans
    23. Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343. PMID: 28642300.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    24. Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. J Clin Pharmacol. 2017 09; 57(9):1183-1193. PMID: 28419486.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    25. Gramatges MM, Deshpande A, Lupo PJ, Rau RE, Redell ML, Horton TM, Scheurer ME, Rabin KR. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9). PMID: 28266784.
      Citations: 3     Fields:    Translation:Humans
    26. Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget. 2016 Nov 15; 7(46):74779-74796. PMID: 27542283.
      Citations: 9     Fields:    Translation:HumansCells
    27. Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. J Hematol Oncol. 2016 09 06; 9(1):82. PMID: 27599459.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    28. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43. PMID: 26884558.
      Citations: 17     Fields:    Translation:Humans
    29. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74. PMID: 26727639.
      Citations: 3     Fields:    Translation:Humans
    30. Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22. PMID: 25833390.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    31. Horton T. Yin and yang of glucocorticoid receptors in apoptosis. Blood. 2015 Jan 08; 125(2):209-11. PMID: 25573965.
      Citations: 1     Fields:    Translation:HumansAnimals
    32. Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60. PMID: 24976003.
      Citations: 21     Fields:    Translation:HumansAnimalsCTClinical Trials
    33. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9. PMID: 24771494.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    34. Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013 Dec; 98(12):1896-904. PMID: 24056819.
      Citations: 22     Fields:    Translation:Humans
    35. Levy AS, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM. Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol. 2013 Aug; 35(6):456-61. PMID: 23892351.
      Citations: 7     Fields:    Translation:Humans
    36. Horton T, Hunger SP. Children are not large mice. Eur J Haematol. 2013 Jun; 90(6):535. PMID: 23534840.
      Citations:    Fields:    Translation:HumansAnimalsCells
    37. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7. PMID: 23554030.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    38. Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T, Keller FG. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013 Jun; 60(6):972-8. PMID: 23255501.
      Citations: 17     Fields:    Translation:Humans
    39. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5. PMID: 22887890.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    40. Horton TM, Sheehan AM, López-Terrada D, Hutchison RE, Narendra S, Wu MF, Liu H. Analysis of NF-?B Pathway Proteins in Pediatric Hodgkin Lymphoma: Correlations with EBV Status and Clinical Outcome-A Children's Oncology Group Study. Lymphoma. 2012; 2012. PMID: 31406604.
    41. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573.
      Citations: 31     Fields:    Translation:HumansCells
    42. Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9. PMID: 21190039.
      Citations: 2     Fields:    Translation:Humans
    43. Frugé E, Margolin J, Horton T, Venkateswaran L, Lee D, Yee DL, Mahoney D. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 01; 55(6):1180-4. PMID: 20589622.
      Citations: 1     Fields:    Translation:Humans
    44. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. PMID: 20127846.
      Citations: 7     Fields:    Translation:Humans
    45. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42. PMID: 19671751.
      Citations: 30     Translation:HumansCells
    46. Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul; 50(7):1174-82. PMID: 19557638.
      Citations: 3     Fields:    Translation:HumansCells
    47. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25. PMID: 19526240.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    48. Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D. Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem. 2009 Sep 15; 392(2):133-8. PMID: 19497291.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    49. Thompson PA, Allen CE, Horton T, Jones JY, Vinks AA, McClain KL. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5. PMID: 19137570.
      Citations: 11     Fields:    Translation:Humans
    50. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92. PMID: 17668866.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    51. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8. PMID: 17971589.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    52. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22. PMID: 17332297.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    53. Min DJ, Moskowitz NP, Brownstein C, Lee H, Horton TM, Carroll WL. Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis. 2006 Nov; 11(11):1977-86. PMID: 17013760.
      Citations: 4     Fields:    Translation:HumansCells
    54. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
      Citations: 39     Fields:    Translation:HumansCells
    55. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9. PMID: 15756014.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    56. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9. PMID: 15570082.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    57. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004 Nov; 145(5):617-21. PMID: 15520760.
      Citations: 6     Fields:    Translation:Humans
    58. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9. PMID: 12679653.
      Citations: 3     Fields:    Translation:Humans
    59. Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD, Gramlich T, Wallace DC. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer. 1996 Feb; 15(2):95-101. PMID: 8834172.
      Citations: 38     Fields:    Translation:HumansCells
    60. Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace DC. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995 Oct; 45(10):1879-83. PMID: 7477986.
      Citations: 30     Fields:    Translation:HumansCells
    61. Wallace DC, Shoffner JM, Trounce I, Brown MD, Ballinger SW, Corral-Debrinski M, Horton T, Jun AS, Lott MT. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995 May 24; 1271(1):141-51. PMID: 7599200.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    62. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 1994 Sep 15; 23(2):471-6. PMID: 7835898.
      Citations: 80     Fields:    Translation:HumansCellsCTClinical Trials
    63. Ranheim TS, Shisler J, Horton TM, Wold LJ, Gooding LR, Wold WS. Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol. 1993 Apr; 67(4):2159-67. PMID: 8445725.
      Citations: 19     Fields:    Translation:AnimalsCells
    64. Gooding LR, Aquino L, Duerksen-Hughes PJ, Day D, Horton TM, Yei SP, Wold WS. The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol. 1991 Jun; 65(6):3083-94. PMID: 1827845.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    65. Horton TM, Tollefson AE, Wold WS, Gooding LR. A protein serologically and functionally related to the group C E3 14,700-kilodalton protein is found in multiple adenovirus serotypes. J Virol. 1990 Mar; 64(3):1250-5. PMID: 2304142.
      Citations: 15     Fields:    Translation:AnimalsCells
    HORTON's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (343)
    Co-Authors (56)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors